Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FibroGen, Inc.

http://www.fibrogen.com

Latest From FibroGen, Inc.

Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave

Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Deal Watch Deals

FibroGen May Have A New Opening For Roxadustat In The US

The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.

Blood & Coagulation Disorders Research & Development

European Approval For Roxadustat Is Silver Lining For FibroGen

The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.

Blood & Coagulation Disorders Commercial

Ellis Unger’s US FDA Farewell Address?

The US FDA advisory committee review of AstraZeneca/FibroGen’s roxadustat for anemia was the last in the long tenure of Office of Cardiology Director Ellis Unger. His opening remarks struck a valedictory tone.

FDA Leadership
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Other Names / Subsidiaries
    • FibroGen China Anemia Holdings Ltd.
    • FibroGen (China) Medical Technology Development Co., Ltd.
    • FibroGen Europe Oy
    • FibroGen International (Cayman) Limited
    • FibroGen International (Hong Kong) Limited
    • Skin Sciences, Inc.
UsernamePublicRestriction

Register